1. A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

3. Relapsed/Refractory B-cell Lymphoma Introduction

4. PI3K Signaling Pathway

5. α and δ PI3K Isoforms

6. Targeted PI3K Inhibitor Therapy

7. Practical Differences

8. Clinical Trial Data

9. Idelalisib

10. Phase 2 Trial of Idelalisib Monotherapy in RR FL

11. Phase 2 Idelalisib Monotherapy AEs of Interest

12. CHRONOS-1 Copanlisib Methods

13. CHRONOS-1 Copanlisib Results

14. Common AEs Associated With Idelalisib and Copanlisib

15. TGR-1202 (Umbralisib)

16. Safety of Umbralisib

17. ASH 2017 Data

18. Phase 3 DUOTM Trial Duvelisib vs Ofatumumab

19. Phase 3 DUOTM Trial Safety & Conclusions

20. Safety Analysis of Umbralisib in R/R Lymphoid Malignancies

21. Safety Analysis of Umbralisib in R/R Lymphoid Malignancies - Results

22. Updated Safety and Efficacy From Copanlisib CHRONOS-1 Trial: Efficacy

23. Updated Safety and Efficacy From Copanlisib CHRONOS-1 Trial: Safety

24. Pooled Safety Analysis From Phase 1 and 2 Studies for Relapsed iNHL Treated With IV Copanlisib

25. Pooled Safety Analysis for Relapsed iNHL Treated With IV Copanlisib, cont.

26. Applying the Data

27. Future Directions

28. Closing Remarks

29. Abbreviations